Compare Verisign, Inc. (VRSN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Verisign, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Verisign, Inc. trades at $287 (market cap $25.51B), while State Street SPDR S&P Biotech ETF trades at $160. The key difference: Verisign, Inc. pays a 1.15% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Verisign, Inc. nearer its low. Which is the better fit depends on your goals.
| VRSN | XBI | |
|---|---|---|
Market Cap | $25.51B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $310.00 | $169.55 |
52-Week Low | $211.49 | $93.43 |
Enterprise Value | $26.82B | — |
Dividend Yield | 1.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VeriSign (VRSN) trades at $282.20, down 3.38% on the day, with a bearish technical signal but strong fundamentals including a 49.77% net income margin and record domain registrations. Recent Q2 2026 earnings beat estimates with EPS of $2.38, though Q4 2025 and Q2 2026 missed expectations. The stock faces headwinds from an antitrust lawsuit filed in September 2026, but institutional buying by firms like BlackRock signals confidence.
Outlook is mixed: bullish analyst consensus with a $328.50 price target suggests 16% upside, supported by AI-driven domain growth and a pending .web delegation. Risks include legal overhangs and competitive pressures. The current valuation at a P/E of 30.64 may limit near-term gains unless earnings accelerate.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
